Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464–77.

Article  CAS  PubMed  Google Scholar 

Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017;14(7):417–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pohl C, Dikic I. Cellular quality control by the ubiquitin-proteasome system and autophagy. Science. 2019;366(6467):818–22.

Article  CAS  PubMed  Google Scholar 

Bard JAM, Goodall EA, Greene ER, et al. Structure and function of the 26S proteasome. Annu Rev Biochem. 2018;87:697–724.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Braten O, Livneh I, Ziv T, et al. Numerous proteins with unique characteristics are degraded by the 26S proteasome following monoubiquitination. Proc Natl Acad Sci U S A. 2016;113(32):E4639-4647.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guang MHZ, Kavanagh EL, Dunne LP, et al. Targeting proteotoxic stress in cancer: a review of the role that protein quality control pathways play in oncogenesis. Cancers (Basel). 2019;11(1):66.

Article  CAS  PubMed  Google Scholar 

Paradzik T, Bandini C, Mereu E, et al. The landscape of signaling pathways and proteasome inhibitors combinations in multiple myeloma. Cancers (Basel). 2021;13(6):1235.

Article  CAS  PubMed  Google Scholar 

Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol. 2006;17(7):1807–19.

Article  CAS  PubMed  Google Scholar 

Schmidt M, Finley D. Regulation of proteasome activity in health and disease. Biochim Biophys Acta. 2014;1843(1):13–25.

Article  CAS  PubMed  Google Scholar 

Kubiczkova L, Pour L, Sedlarikova L, et al. Proteasome inhibitors—molecular basis and current perspectives in multiple myeloma. J Cell Mol Med. 2014;18(6):947–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang J, Wang Y, He S, et al. Proteasome inhibition induces macrophage apoptosis via mitochondrial dysfunction. J Biochem Mol Toxicol. 2021;35(11): e22894.

Article  CAS  PubMed  Google Scholar 

Zhang M, Yuan X, Xu B, et al. Anticancer effect of a novel proteasome inhibitor, YSY01A, via G2/M arrest in PC-3M cells in vitro and in vivo. J Cancer. 2015;6(8):701–8.

Article  PubMed  PubMed Central  Google Scholar 

Yin D, Zhou H, Kumagai T, et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene. 2005;24(3):344–54.

Article  CAS  PubMed  Google Scholar 

Greene ER, Dong K, Martin A. Understanding the 26S proteasome molecular machine from a structural and conformational dynamics perspective. Curr Opin Struct Biol. 2020;61:33–41.

Article  CAS  PubMed  Google Scholar 

Davis C, Spaller BL, Matouschek A. Mechanisms of substrate recognition by the 26S proteasome. Curr Opin Struct Biol. 2021;67:161–9.

Article  CAS  PubMed  Google Scholar 

Rabl J, Smith DM, Yu Y, et al. Mechanism of gate opening in the 20S proteasome by the proteasomal ATPases. Mol Cell. 2008;30(3):360–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ding Z, Xu C, Sahu I, et al. Structural snapshots of 26S proteasome reveal tetraubiquitin-induced conformations. Mol Cell. 2019;73(6):1150-1161.e6.

Article  CAS  PubMed  Google Scholar 

Hempel D, Wojtukiewicz MZ, Kozłowski L, et al. Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors. Tumour Biol. 2011;32(4):753–9.

Article  CAS  PubMed  Google Scholar 

Cavo M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia. 2006;20(8):1341–52.

Article  CAS  PubMed  Google Scholar 

Kozalak G, Bütün İ, Toyran E, et al. Review on bortezomib resistance in multiple myeloma and potential role of emerging technologies. Pharmaceuticals (Basel). 2023;16(1):111.

Article  CAS  PubMed  Google Scholar 

Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 2008;14(6):1649–57.

Article  CAS  PubMed  Google Scholar 

Kortuem KM, Stewart AK. Carfilzomib. Blood. 2013;121(6):893–7.

Article  CAS  PubMed  Google Scholar 

Herndon TM, Deisseroth A, Kaminskas E, et al. U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res. 2013;19(17):4559–63.

Article  CAS  PubMed  Google Scholar 

Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19(7):953–64.

Article  CAS  PubMed  Google Scholar 

Gentile M, Offidani M, Vigna E, et al. Ixazomib for the treatment of multiple myeloma. Expert Opin Invest Drugs. 2015;24(9):1287–98.

Article  CAS  Google Scholar 

Gupta N, Hanley MJ, Xia C, et al. Clinical pharmacology of Ixazomib: the first oral proteasome inhibitor. Clin Pharmacokinet. 2019;58(4):431–49.

Article  CAS  PubMed  Google Scholar 

Tzogani K, Florez B, Markey G, et al. European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. ESMO Open. 2019;4(5): e000570.

Article  PubMed  PubMed Central  Google Scholar 

Zhang J, Sun S, Liu J, et al. Discovery of a novel ubenimex derivative as a first-in-class dual CD13/proteasome inhibitor for the treatment of cancer. Molecules. 2023;28(17):6343.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang X, Adwal A, Turner AG, et al. New peptidomimetic boronates for selective inhibition of the chymotrypsin-like activity of the 26S proteasome. ACS Med Chem Lett. 2016;7(12):1039–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dan S, Tsunoda T, Kitahara O, et al. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 2002;62(4):1139–47.

CAS  PubMed  Google Scholar 

Kong D, Yamori T. JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs. Bioorg Med Chem. 2012;20(6):1947–51.

Article  CAS  PubMed